Biodexa Pharmaceuticals Plc (BDRX)
- Previous Close
1.1000 - Open
1.1600 - Bid 1.1100 x 400
- Ask 1.1400 x 400
- Day's Range
1.0900 - 1.1800 - 52 Week Range
0.6700 - 20.4000 - Volume
194,349 - Avg. Volume
2,990,447 - Market Cap (intraday)
4.955M - Beta (5Y Monthly) 1.53
- PE Ratio (TTM)
-- - EPS (TTM)
-10.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
www.biodexapharma.comRecent News: BDRX
Performance Overview: BDRX
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BDRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BDRX
Valuation Measures
Market Cap
4.82M
Enterprise Value
-2.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.82
Price/Book (mrq)
0.82
Enterprise Value/Revenue
-0.50
Enterprise Value/EBITDA
0.03
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-51.38%
Return on Equity (ttm)
-180.59%
Revenue (ttm)
381k
Net Income Avi to Common (ttm)
-7.08M
Diluted EPS (ttm)
-10.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
5.97M
Total Debt/Equity (mrq)
9.92%
Levered Free Cash Flow (ttm)
348.88k
Research Analysis: BDRX
Company Insights: BDRX
BDRX does not have Company Insights